BMS-954561 + BMS-954561 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post-Herpetic Neuralgia (PHN)
Conditions
Post-Herpetic Neuralgia (PHN)
Trial Timeline
Mar 1, 2011 → Jun 1, 2012
NCT ID
NCT01305538About BMS-954561 + BMS-954561 + Placebo
BMS-954561 + BMS-954561 + Placebo is a phase 2 stage product being developed by Bristol Myers Squibb for Post-Herpetic Neuralgia (PHN). The current trial status is completed. This product is registered under clinical trial identifier NCT01305538. Target conditions include Post-Herpetic Neuralgia (PHN).
What happened to similar drugs?
1 of 1 similar drugs in Post-Herpetic Neuralgia (PHN) were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01305538 | Phase 2 | Completed |
Competing Products
5 competing products in Post-Herpetic Neuralgia (PHN)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + DS-5565 | Daiichi Sankyo | Pre-clinical | 26 |
| ASP8477 + Placebo | Astellas Pharma | Phase 2 | 35 |
| EMA401 + Placebo | Novartis | Phase 2 | 27 |
| pregabalin | Pfizer | Approved | 43 |
| HSK16149，probenecid, cimetidine | Haisco Pharmaceutical Group | Phase 1 | 29 |